Global Patient Registry of Inherited Retinal Diseases
NCT05957276
Recruiting
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
Gender:
ALL
Ages:
3 years and above
Trial Updated:
04/25/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +70 locations
Conditions: Inherited Retinal Diseases
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441
Recruiting
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +9 locations
Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Register for Updates
Exposure Therapy Study In Adults With Eating Disorders
NCT06171711
Recruiting
The current proposal will evaluate the feasibility, acceptability, and preliminary efficacy of Exposure Therapy for anorexia nervosa (AN) spectrum disorders (Exp-AN), an innovative treatment rooted in principles of inhibitory learning. Exp-AN will target anxiety about both eating and weight gain by combining in vivo (i.e., in real life) and imaginal (i.e., mental) exposure in novel ways (e.g., eating a feared food while listening to a recording describing fears about weight gain).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: 905 W Govener Rd, Hershey, Pennsylvania
Conditions: Eating Disorders, Anorexia Nervosa
Register for Updates
RECOVER-AUTONOMIC Platform Protocol
NCT06305780
Recruiting
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: East Alabama Medical Center - Appendix B Only, Opelika, Alabama +49 locations
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Southern Cancer Center, PC, Daphne, Alabama +121 locations
Conditions: Breast Cancer
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Site 36, La Jolla, California +114 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192
Recruiting
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/25/2025
Locations: Stanford University Medical Center, Stanford, California +7 locations
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Register for Updates
Thermogenenic Responses to Fasting and Overfeeding in Women
NCT06610162
Recruiting
This study plans to learn more about why menopause increases the risk of weight gain. During and after menopause, women are prone to increased weight gain. The weight gained is primarily body fat, particularly visceral or abdominal body fat. The excess gain in abdominal fat during menopause increases the risk of chronic metabolic diseases such as heart disease and diabetes. The increase in weight and body fat with menopause may be due to changes in metabolism related to the loss of estrogen. Thi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Obesity
Register for Updates
MMA Embolization for Refractory Chronic Migraine
NCT06735833
Recruiting
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: Mount Sinai, New York, New York +4 locations
Conditions: Migraine
Register for Updates
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012
Recruiting
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/25/2025
Locations: Chandler Clinical Trials, Chandler, Arizona +23 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447
Recruiting
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: START Mountain Region ( Site 0008), West Valley City, Utah +3 locations
Conditions: Ovarian Cancer Recurrent
Register for Updates
Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI)
NCT06939946
Recruiting
It is often challenging to tell apart the parathyroid glands from the surrounding area such as lymph nodes, fat and thyroid tissue. If the surgeons are not able to tell where the parathyroid glands are, they might accidentally be removed or damaged. This can lead to complications such as hypocalcemia (low calcium level) requiring treatment and sometimes lead to longer hospital stay. This study is designed to test a new method (a non-invasive hand-held imaging device) to assist surgeons in identi... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/25/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Thyroid Disease, Thyroid Surgery, Parathyroid Gland
Register for Updates